Cargando…

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review

Bipolar androgen therapy (BAT) is a new endocrinologic treatment for castration-resistant prostate cancer (CRPC) that can restore some patients’ sensitivity to drugs such as abiraterone (Abi) and enzalutamide (Enz). We performed a meta-analysis using STATA16. Sensitivity analyses were performed by e...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Xiangyun, Huang, Shan, Wang, Xin’an, Yi, Cheng, Gong, Niandong, Yu, Junfeng, Xu, Chengdang, Xiang, Zhendong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127253/
https://www.ncbi.nlm.nih.gov/pubmed/37113653
http://dx.doi.org/10.3389/fendo.2022.1125838
_version_ 1785030424666308608
author You, Xiangyun
Huang, Shan
Wang, Xin’an
Yi, Cheng
Gong, Niandong
Yu, Junfeng
Xu, Chengdang
Xiang, Zhendong
author_facet You, Xiangyun
Huang, Shan
Wang, Xin’an
Yi, Cheng
Gong, Niandong
Yu, Junfeng
Xu, Chengdang
Xiang, Zhendong
author_sort You, Xiangyun
collection PubMed
description Bipolar androgen therapy (BAT) is a new endocrinologic treatment for castration-resistant prostate cancer (CRPC) that can restore some patients’ sensitivity to drugs such as abiraterone (Abi) and enzalutamide (Enz). We performed a meta-analysis using STATA16. Sensitivity analyses were performed by examining the effects of individual studies using different effect models and detecting any publication bias using the Harbord test. In a total of 108 unique records, ten studies were included in the final meta-analysis. Participants who underwent BAT achieved a PSA50 response rate of 27% (95%CI [0.22,0.31], I2=17.98%), ORR of 34% (95%CI [0.24,0.43], I2=0), and incidence of AEs (grade≥3) of 14% (95%CI [0.09,0.19], I2=0). Patients who completed BAT proceeded to AR-targeted therapy (Abi or Enz) and achieved a PSA50 response rate of 57% (95% CI [0.36,0.78], I2=0). Patients with prior Enz resistance had a stronger impact on the PSA50 of AR-target therapy rechallenge. The results of this meta-analysis indicate that BAT is a safe and effective treatment for patients who have progressed after Abi or Enz. BAT can trigger the resensitization of patients with CRPC to subsequent endocrine therapy and improve the overall survival of patients and their quality of life.
format Online
Article
Text
id pubmed-10127253
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101272532023-04-26 Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review You, Xiangyun Huang, Shan Wang, Xin’an Yi, Cheng Gong, Niandong Yu, Junfeng Xu, Chengdang Xiang, Zhendong Front Endocrinol (Lausanne) Endocrinology Bipolar androgen therapy (BAT) is a new endocrinologic treatment for castration-resistant prostate cancer (CRPC) that can restore some patients’ sensitivity to drugs such as abiraterone (Abi) and enzalutamide (Enz). We performed a meta-analysis using STATA16. Sensitivity analyses were performed by examining the effects of individual studies using different effect models and detecting any publication bias using the Harbord test. In a total of 108 unique records, ten studies were included in the final meta-analysis. Participants who underwent BAT achieved a PSA50 response rate of 27% (95%CI [0.22,0.31], I2=17.98%), ORR of 34% (95%CI [0.24,0.43], I2=0), and incidence of AEs (grade≥3) of 14% (95%CI [0.09,0.19], I2=0). Patients who completed BAT proceeded to AR-targeted therapy (Abi or Enz) and achieved a PSA50 response rate of 57% (95% CI [0.36,0.78], I2=0). Patients with prior Enz resistance had a stronger impact on the PSA50 of AR-target therapy rechallenge. The results of this meta-analysis indicate that BAT is a safe and effective treatment for patients who have progressed after Abi or Enz. BAT can trigger the resensitization of patients with CRPC to subsequent endocrine therapy and improve the overall survival of patients and their quality of life. Frontiers Media S.A. 2023-04-11 /pmc/articles/PMC10127253/ /pubmed/37113653 http://dx.doi.org/10.3389/fendo.2022.1125838 Text en Copyright © 2023 You, Huang, Wang, Yi, Gong, Yu, Xu and Xiang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
You, Xiangyun
Huang, Shan
Wang, Xin’an
Yi, Cheng
Gong, Niandong
Yu, Junfeng
Xu, Chengdang
Xiang, Zhendong
Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
title Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
title_full Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
title_fullStr Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
title_full_unstemmed Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
title_short Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
title_sort efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: a systematic review
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127253/
https://www.ncbi.nlm.nih.gov/pubmed/37113653
http://dx.doi.org/10.3389/fendo.2022.1125838
work_keys_str_mv AT youxiangyun efficacyandsafetyofbipolarandrogentherapyincastrationresistantprostatecancerfollowingabirateroneorenzalutamideresistanceasystematicreview
AT huangshan efficacyandsafetyofbipolarandrogentherapyincastrationresistantprostatecancerfollowingabirateroneorenzalutamideresistanceasystematicreview
AT wangxinan efficacyandsafetyofbipolarandrogentherapyincastrationresistantprostatecancerfollowingabirateroneorenzalutamideresistanceasystematicreview
AT yicheng efficacyandsafetyofbipolarandrogentherapyincastrationresistantprostatecancerfollowingabirateroneorenzalutamideresistanceasystematicreview
AT gongniandong efficacyandsafetyofbipolarandrogentherapyincastrationresistantprostatecancerfollowingabirateroneorenzalutamideresistanceasystematicreview
AT yujunfeng efficacyandsafetyofbipolarandrogentherapyincastrationresistantprostatecancerfollowingabirateroneorenzalutamideresistanceasystematicreview
AT xuchengdang efficacyandsafetyofbipolarandrogentherapyincastrationresistantprostatecancerfollowingabirateroneorenzalutamideresistanceasystematicreview
AT xiangzhendong efficacyandsafetyofbipolarandrogentherapyincastrationresistantprostatecancerfollowingabirateroneorenzalutamideresistanceasystematicreview